Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business. Operating Highlights Entered sponsored research agreement with Columbia University to develop…

Source

Previous articlePharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
Next articleMydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021